- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SNY
Recent news which mentions SNY
Canada Approves First Plant-Based COVID-19 Vaccine
February 25, 2022
From Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
February 24, 2022
From Benzinga
Why Moderna Stock Is Falling Today
February 23, 2022
From Motley Fool
From Benzinga
2 Green Flags for Novavax's Future
February 23, 2022
From Motley Fool
WHO says omicron subvariant is not stopping global cases from falling, and U.S. nearing 940,000 COVID deaths
February 23, 2022
From MarketWatch
From MarketWatch
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
February 18, 2022
From Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
From Benzinga
From Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
February 16, 2022
Tags
NASDAQ:HRMY,NASDAQ:SDGR,NASDAQ:PTGX,NYSEARCA:XBI,NASDAQ:SNY,NYSE:BMY,NASDAQ:AGIO,NYSE:JNJ
Market News
HRMY
From InvestorPlace
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
February 16, 2022
From Motley Fool
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
Could This New Indication Create a Blockbuster for Pfizer?
February 05, 2022
From Motley Fool
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
From Benzinga
From Benzinga
Earnings Scheduled For February 4, 2022
February 04, 2022
From Benzinga
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
February 02, 2022
From Benzinga
Is AbbVie Stock a Buy Now?
February 01, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
From Benzinga
5 Things To Expect This Week
January 31, 2022
From InvestorPlace
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.